Program « SOHO 2019

SCIENTIFIC PROGRAM

audience_SOHO18_Sep12_0127_665x445

SOHO 2019 Program

The Society of Hematologic Oncology’s Seventh Annual Meeting will be held on September 11-14, 2019. This 3.5-day program will focus on state-of-the-art approaches and will include a variety of educational formats including: general sessions, meet-the-professor sessions, breakfast with the expert, debates and plenary sessions. Note that some sessions have changed since the last annual meeting. SOHO members will be notified of program updates. To sign up for FREE SOHO membership, go to the SOHO membership site.

DOWNLOAD PROGRAM

SOHO MEMBER SIGN-UP

REGISTER NOW

WEDNESDAY, SEPTEMBER 11, 2019
TIME TOPIC/SESSION SPEAKER AFFILIATION/ROOM
INDEPENDENT SATELLITE SYMPOSIUM I
6:15 AM Waldenström Macroglobulinemia: Expert Insights on Current and Emerging Treatment Options
&nbsp Meletios Dimopoulos, MD and Joshua Richter, MD
&nbsp This CME activity is jointly provided by RedMedEd and Purdue University College of Pharmacy. This activity is supported by educational grants from Pharmacyclics, an AbbVie Company and Janssen Biotech. For more information and to register for this ISS, go to https://education.redmeded.com/a/ZDUJOX?utm_source=ce&utm_medium=catalog
BREAKFAST WITH THE EXPERT I
6:45 AM Breakfast with the Expert: Optimizing Care for the Older Adolescent and Young Adult: Perspectives from Two Sides of the Ocean  Wendy Stock, MD The University of Chicago, Chicago, Illinois, USA
Nicolas Boissel, MD, PhD Hôpital Saint-Louis , Paris, France
7:45 AM BREAK
MEET-THE-PROFESSOR SESSIONS
8:00 AM MTP Session I: CML
  Session Chair: Delphine Rea
  New Kinase Inhibitors for CML Michael J. Mauro, MD, PhD Memorial Sloan-Kettering Cancer Center, New York, New York, USA
  Biomarkers To Predict TFR – How Close Are We? Timothy P. Hughes, MD, FRACP, FRCPA South Australian Health and Medical Research Institute, Adelaide, Australia
  Novel Approaches to Blast Crisis CML Elias Jabbour, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
8:00 AM MTP Session II: ALL
  Session Chair: Ching-Hon Pui
  Targeted Cellular Therapy for ALL  Partow Kebriaei, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  Childhood ALL: How To Cure The Very High Risk? Ching-Hon Pui, MD St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
  The Future of ALL Treatment Nicolas Boissel, MD, PhD Hôpital Saint-Louis , Paris, France
8:00 AM MTP Session III: AML
  Session Chair: Farhad Ravandi
  Harnessing the Immune System for Treating AML Farhad Ravandi, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  Manipulating the Microenvironment in AML Daniel J. DeAngelo, MD, PhD Dana-Farber Cancer Institute, Boston, Massachusetts, USA
  IDH Inhibitors in AML Courtney D. DiNardo, MD, MSCE The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
8:00 AM MTP Session IV: MPN
  Session Chair: Elliott Winton
  Identification for and Management of Patient with PV and MF with Ruxolitinib Srdan Verstovsek, MD, PhD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  Combination Approaches With Ruxolitinib in MF Laura C. Michaelis, MD Medical College of Wisconsin, Milwaukee, Wisconsin, USA
  MF Management After Ruxolitinib Failure Elliott F. Winton, MD Emory University Hospital, Atlanta, Georgia, USA
8:00 AM MTP Session V: NHL
  Session Chair: Kieron Dunleavy
  Double Hit Lymphoma Kieron M. Dunleavy, MD George Washington University Cancer Center, Washington, DC, USA
  Is There A Role for BCL2 Inhibitors in DLBCL Andrew D. Zelenetz, MD, PhD Memorial Sloan-Kettering Cancer Center, New York, New York, USA
  How to Treat Elderly Patients with CHL Alison J. Moskowitz, MD Memorial Sloan-Kettering Cancer Center, New York, New York, USA
8:00 AM MTP Session VI: MDS
  Session Chair: Lucy Godley
  Pre-MDS: CHIP, CCUS, ICUS Lucy A. Godley, MD, PhD The University of Chicago, Chicago, Illinois, USA
  Management of Lower Risk MDS Rami Komrokji, MD H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
  Management of Higher Risk MDS Valeria Santini, MD University of Florence, Florence, Italy
8:00 AM MTP Session VII: CLL
  Session Chair: Neil Kay
  Genetics of CLL Richard Rosenquist Brandell, MD, PhD Karolinska Institutet, Stockholm, Sweden
  Clonal Evolution in CLL Davide Rossi, MD, PhD Institute of Oncology Research, Bellinzona, Switzerland
  Mechanisms of Resistance in CLL Paolo Ghia, MD, PhD Università Vita-Salute San Raffaele, Milano, Italy
8:00 AM MTP Session VIII: MM
  Session Chair: Sagar Lonial
  What Is The Optimal Induction Therapy for MM Amrita Y. Krishnan, MD, FACP City of Hope National Medical Center, Duarte, California, USA
  Real World Treatment of Patients with Relapsed/Refractory Disease Meletios Dimopoulos, MD University of Athens, Athens, Greece
8:00 AM MTP Session X: Cellular Therapy
  Session Chair: Sergio Giralt
  Setting Up a CAR T Program Ins and Outs Sergio Giralt, MD Memorial Sloan-Kettering Cancer Center, New York, New York, USA
9:15 AM BREAK
SESSION I: CHRONIC MYELOID LEUKEMIA
Session Chairs: Timothy Hughes and Michael Deininger
9:30 AM Welcome and Opening Remarks Ching-Hon Pui, MD President, Society of Hematologic Oncology
9:40 AM CML: State of the Art Update Jorge Cortés, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
9:55 AM Therapeutic Innovations in CML Michael Deininger, MD, PhD Huntsman Cancer Hospital, The University of Utah, Salt Lake City, Utah, USA
10:10 AM TFR: Impact of Depth and Duration of Response Delphine Rea, MD, PhD Hôpital Saint Louis, Paris, France
10:25 AM Case Presentation: Treatment Choices: Impact of Comorbidities Timothy P. Hughes, MD, FRACP, FRCPA South Australian Health and Medical Research Institute, Adelaide, Australia
10:40 AM Case Presentation: Allograft Versus Third-Line Therapy Michael J. Mauro, MD, PhD Memorial Sloan-Kettering Cancer Center, New York, New York, USA
10:55 AM Oral Abstract
CML-044 | ENESTop 192-Weeks Results: Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After Stopping Second-Line Nilotinib
Francois-Xavier Mahon, MD, PhD Cancer Center of Bordeaux, Institut Bergonié, University of Bordeaux, Bordeaux, France
11:05 AM Oral Abstract
CML-041 | Combination of Asciminib, a Novel and Specific BCR-ABL1 Inhibitor, Plus Imatinib in Previously Treated Chronic Myeloid Leukemia (CML) Patients: Phase 1 Study Results
Moshe Talpaz, MD University of Michigan, Ann Arbor, Michigan, USA
SESSION II: MYELOPROLIFERATIVE NEOPLASMS
Session Chairs: Robert Kralovics and David Snyder
11:15 AM MPN State of the Art Update: Stem Cell Niche in MPN Robert Kralovics, PhD Medical University of Vienna, Vienna, Austria
11:30 AM Primer on CNL and aCML Diagnosis and Therapy Uma Borate, MD, MS Oregon Health & Science University, Portland, Oregon, USA
11:45 AM Identifying and Treating “Progression” in MF Prithviraj Bose, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
12:00 PM Evolution of Transplant Approaches in MPN David S. Snyder, MD, FACP City of Hope National Medical Center, Durate, California, USA
12:15 PM Immunogenicity of MPN: A New Way Forward? Robert Kralovics, PhD Medical University of Vienna, Vienna, Austria
12:30 PM Oral Abstract
MPN 352 | Fedratinib Induces Spleen Responses and Reduces Symptom Burden as First-line or Salvage Therapy in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) and Low Platelet Counts
Ruben Mesa, MD University of Texas Health Science Center at San Antonio, San Antonio, USA
12:40 PM Oral Abstract
MPN 398 | Integrative Sequencing of Myeloproliferative Neoplasms
Kristen M. Pettit, MD University of Michigan, Ann Arbor, Michigan, USA
INDUSTRY EXPERT LUNCH SESSION I
12:50 PM Jakafi in Patients with Polycythemia Vera who have an Inadequate Response to Hydroxyurea
This activity is supported by Incyte
PLENARY SESSION I
Session Chair: Hagop Kantarjian
2:20 PM Impact of Molecular Signature on Prognostication in MPN Ayalew Tefferi, MD Mayo Clinic Rochester, Rochester, Minnesota, USA
Recipient of the SOHO 2019 Distinguished Lecturer Award
SESSION III: MULTIPLE MYELOMA
Session Chairs: Sagar Lonial and Robert Orlowski
2:40 PM Non-Antibody Based Immune Therapy Nina Shah, MD University of California San Francisco, San Francisco, California, USA
2:55 PM Role of HDT in MM: 2019 Maria-Victoria Mateos, MD, PhD University Hospital of Salamanca, Spain
3:10 PM Bone Disease and Management Jens Hillengass, MD Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA
3:25 PM BREAK
3:55 PM Debate: Can MRD Be Used for Treatment Decisions? YES Jeffrey L. Wolf, MD University of California San Francisco, San Francisco, California, USA
4:10 PM Debate: Can MRD Be Used for Treatment Decisions? NO Thomas G. Martin, MD University of California San Francisco, San Francisco, California, USA
4:25 PM Amyloid Therapy and Targets Suzanne Lentzsch, MD, PhD Columbia University and at New York Presbyterian Hospital, New York, USA
4:40 PM Induction Therapy for Newly Diagnosed MM: What to Use in the Era of Monoclonal Antibodies Ajay K. Nooka, MD, MPH, FACP Winship Cancer Institute of Emory University, Atlanta, Georgia, USA
4:55 PM Oral Abstract
MM 250 | HORIZON (OP-106) Study of Melflufen in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Daratumumab and/or Pomalidomide: Updated Efficacy and Safety
TBD  
5:05 PM Oral Abstract
MM 256 | Primary Treatment of Light Chain (AL) Amyloidosis with Bortezomib, Lenalidomide and Dexamethasone (VRD)
Ioanna Dialoupi, MD Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
5:15 PM ADJOURN
POSTER SESSION & WELCOME RECEPTION
5:15 PM Poster Session, Welcome Reception and Awards
INDEPENDENT SATELLITE SYMPOSIUM IB
8:00 PM Evolving Practices in AML: A Case-based Guide to New and Emerging Treatment Options
Naval Daver, MD; Eunice S. Wang, MD; Courtney D. DiNardo, MD, MSCE
This CME activity is provided by MediCom Worldwide, Inc. This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Pfizer., and Jazz Pharmaceuticals. For more information and to register for this ISS, go to TBD
THURSDAY, SEPTEMBER 12, 2019
TIME TOPIC/SESSION SPEAKER AFFILIATION/ROOM
INDEPENDENT SATELLITE SYMPOSIUM II
6:15 AM The BiTE Platform and Emerging Targets in Hematologic Malignancies
This activity is provided by Amgen.
BREAKFAST WITH THE EXPERT II
6:45 AM BCL-2 Inhibition in AML Marina Konopleva, MD, PhD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
7:45 AM BREAK
SESSION IV: ACUTE LYMPHOBLASTIC LEUKEMIA
Session Chairs: Wendy Stock and Dieter Hoelzer
8:00 AM CAR-T therapy for ALL:  Moving Beyond Single Agent Targeting  Nirali N. Shah, MD, MHSc Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
8:15 AM Debate: Is Transplant Still Necessary in the Era of Targeted Cellular Therapy for ALL?  PRO Partow Kebriaei, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
8:30 AM Debate: Is Transplant Still Necessary in the Era of Targeted Cellular Therapy for ALL?  CON Michael A. Pulsipher, MD Children’s Hospital Los Angeles, University of Southern California, Los Angeles, California, USA
8:45 AM Combining Genotype Profiling with MRD for More Accurate Prognostication in ALL Jack Bartram, MD Great Ormond Street Hospital for Children, NHS Foundation Trust, London, United Kingdom
9:00 AM Ph+ ALL: How Can We Optimize Treatment for All Patients? Sabina Chiaretti, MD, PhD La Sapienza University, Rome, Italy
9:15 AM Progress in the Management of Adult ALL Dieter Hoelzer, MD, PhD Onkologikum, Frankfurt am Museumsufer, Germany
9:30 AM Novel Therapies in Older Patients with Ph- B-Cell ALL Elias Jabbour, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
9:45 AM The Challenge of Improving Outcomes for T-ALL: Approach to ETP ALL and Relapsed Disease Bijal D. Shah, MD H. Lee Moffitt Cancer Center, Tampa, Florida, USA
10:00 AM Oral Abstract
ALL 169 | Duplex Sequencing Identifies Low Level ABL1 Kinase Domain Mutations in Untreated Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Nicholas Short, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
10:10 AM Oral Abstract
ALL 221 | More or Less? Impact of Dose Number on Outcomes of Patients with Acute Lymphoblastic Leukemia Treated with Inotuzumab Ozogamicin
Elias Jabbour, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
10:20 AM BREAK
SESSION V: MYELODYSPLASTIC SYNDROMES
Session Chairs: Guillermo Garcia-Manero and Amit Verma
10:50 AM MDS State of the Art Update: Emerging Targeted Therapeutics for MDS Guillermo Garcia-Manero, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
11:05 AM Progress in Targeting the TGFb Pathway Amit Verma, MD Albert Einstein College of Medicine, Bronx, New York, USA
11:20 AM Case Presentation: Managing TP53-Mutant MDS David Sallman, MD H. Lee Moffitt Cancer Center, Tampa, Florida, USA
11:35 AM Case Presentation: Iron Chelation Therapy – The Final Answer Emanuele Angelucci, MD Ospedale Policlinico San Martino, Genova, Italy
11:50 AM Novel Chromatin Modulation Strategies In MDS Michael R. Savona, MD Vanderbilt University Medical Center, Nashville, Tennessee, USA
12:05 PM Preventing Relapse Following Allogenic Stem Cell Transplant Uwe  Platzbecker, MD, PhD University Hospital “Carl Gustav Carus”, Dresden, King’s College London, Dresden, Germany
12:20 PM Oral Abstract
MDS 300 | Ring Sideroblast Quantification is Highly Predictive of TP53 Mutation in MDS with Excessive Blasts with Prognostic Implications
David Swoboda, MD H. Lee Moffitt Cancer Center, Tampa, Florida, USA
12:30 PM Oral Abstract
MDS 363 | Demographics and Survival in Atypical Chronic Myeloid Leukemia: SEER Data Analysis
Nwabundo Anusim, MD Beaumont Hospital, Oakland University, Royal Oak, Michigan, USA
INDUSTRY EXPERT LUNCH SESSION II
12:40 PM DARZALEX®-Based Combination Regimens for Multiple Myeloma
This activity is supported by Janssen
PLENARY SESSION II
Session Chair: Ching-Hon Pui, MD
2:10 PM Can the Newest Insights In the Molecular Pathogenesis of B-ALL Lead to New Therapeutic Targets? Charles G. Mullighan, MBBS (Hons), MSc, MD St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
SESSION VI: ACUTE MYELOID LEUKEMIA
Session Chairs: Richard Stone and Eunice Wang
2:30 PM AML State of the Art Update Selina M. Luger, MD University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, USA
2:45 PM CART Cells in AML Stephen J. Forman, MD City of Hope National Medical Center, Duarte, California, USA
3:00 PM Novel Strategies in High Risk AML John S. Welch, MD, PhD Washington University School of Medicine, St. Louis, Missouri, USA
3:15 PM ADC, DARTs and Bites in AML John DiPersio, MD, PhD Washington University School of Medicine, St. Louis, Missouri, USA
3:30 PM Debate: Should All Older AML Patients and Younger Patients with Adverse Biology Routinely Receive HMA/Ventoclax Instead of 3+7/Standard Induction? PRO Daniel Pollyea, MD, MS University of Colorado, Denver, Colorado, USA
3:45 PM Debate: Should All Older AML Patients and Younger Patients with Adverse Biology Routinely Receive HMA/Ventoclax Instead of 3+7/Standard Induction? CON Jeffrey E. Lancet, MD H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
4:00 PM BREAK
4:30 PM Use of MRD in AML Pau Montesinos, MD University Hospital La Fe, Valencia, Spain
4:45 PM Use of FLT3 Inhibitors in AML Catherine Smith, MD University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA
5:00 PM Use of Gemtuzumab in AML Roland B. Walter, MD, PhD Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, Washington, USA
5:15 PM Oral Abstract
AML 212 | Synergistic Activity of the MCL-1 Inhibitor S63845 with Midostaurin in Preclinical Human Models of FLT3-ITD Mutated Acute Myeloid Leukemia (AML)
Anna Skwarska, MD The University of Oxford, Oxford, United Kingdom
5:25 PM Oral Abstract
AML 197 | Mutant IDH1 Inhibitor Ivosidenib (IVO; AG-120) in Combination with Azacitidine (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)
Courtney D. DiNardo, MD, MSCE The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
5:35 PM Oral Abstract
AML 231 | CRISPR-Cas9 Screen Identifies XPO7 as a Novel Therapeutic Target for TP53-Mutated AML
Yuchiro Semba, MD Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
INDUSTRY EXPERT DINNER SESSION III
5:45 PM CML: Where We Are and What We Need
This activity is supported by Novartis
FRIDAY, SEPTEMBER 13, 2019
TIME TOPIC/SESSION SPEAKER AFFILIATION/ROOM
INDEPENDENT SATELLITE SYMPOSIUM III
6:15 AM Current & Future Directions in Chronic and Acute Leukemias
This CME activity is jointly provided by the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend. This activity is supported by educational grants from Pfizer.
For more information and to register for this ISS, go to www.bioascend.com/SOHOLeukemia
BREAKFAST WITH THE EXPERT III
6:45 AM Breakfast with the Expert: Marginal Zone Lymphoma Emanuele Zucca, MD Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
7:45 AM BREAK    
SESSION VII: HODGKIN LYMPHOMA
Session Chairs: Pier Luigi Zinzani and Stephen Ansell
8:00 AM Early Stage HL Andrew M. Evens, DO, MSc, FACP Rutgers Cancer Institute, New Brunswick, New Jersey, USA
8:15 AM Advanced Stage HL Pier Luigi Zinzani, MD University of Bologna, Bologna, Italy
8:30 AM Oral Abstract
   
SESSION IX: INDOLENT B-CELL LYMPHOMA
Session Chairs: Nathan Fowler and Robert Marcus
8:40 AM Chemo Free vs Chemotherapy Based Front Line Therapy Nathan H. Fowler, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
8:55 AM CD20-Based Bi-Specific Antibody Therapy Martin Hutchings, MD, PhD The Finsen Center, National Hospital Copenhagen University Hospital, Copenhagen, Denmark
9:10 AM PI3K Inhibitors Andrew D. Zelenetz, MD, PhD Memorial Sloan-Kettering Cancer Center, New York, New York, USA
9:25 AM Optimal Use of Bendamustine in FL Mathias J. Rummel, MD, PhD Justus-Liebig University-Hospital, Giessen, Germany
9:40 AM Role of Radiation Therapy in The Management of Gastric MALT Lymphoma Joachim Yahalom, MD, FACR Memorial Sloan-Kettering Cancer Center, New York, New York, USA
9:55 AM Oral Abstract
   
10:05 AM BREAK    
SESSION X: AGGRESSIVE B-CELL LYMPHOMA
Session Chair: Anas Younes and Laurie Sehn
10:35 AM Is There A Role for RCHOP + Drug X Strategy Anas Younes, MD Memorial Sloan-Kettering Cancer Center, New York, New York, USA
10:50 AM CAR T-Cells  David G. Maloney, MD, PhD Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
11:05 AM Antibody Drug Conjugates Laurie Sehn, MD The University of British Columbia, Vancouver, Canada
11:20 AM CNS Toxicity of CAR T-Cell Therapy Bianca D. Santomasso, MD, PhD Memorial Sloan-Kettering Cancer Center, New York, New York, USA
11:35 AM Oral Abstract
   
11:45 AM Oral Abstract
   
11:55 AM Oral Abstract
   
INDUSTRY EXPERT LUNCH SESSION IV
12:05 PM Understanding YESCARTA® CAR T Therapy
This activity is supported by Gilead
PLENARY SESSION III
Session Chair: Sergio Giralt
1:35 PM Future of Cellular Therapy Elizabeth J. Shpall, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
SESSION VIII: T-CELL LYMPHOMA
Session Chairs: Julie Vose and Philippe Gaulard
1:55 PM New Frontline Regimens Julie Vose, MD, MBA University of Nebraska Medical Center, Omaha, Nebraska
2:10 PM New Therapy for Relapsed T-Cell Lymphoma Owen A. O’Connor, MD, PhD. Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, USA
2:25 PM New Insights into the Molecular Pathogenesis of T-Cell Lymphoma Philippe Gaulard, MD Hôpital Henri Mondor, Paris, France
2:40 PM Oral Abstract
   
2:50 PM BREAK    
SESSION XI: MANTLE CELL LYMPHOMA
Session Chair: Simon Rule and Andrew Zelenetz
3:20 PM What Is the Standard Front Line Therapy for MCL? Simon Rule, MD University of Plymouth, Derriford Hospital, Plymouth, United Kingdom
3:35 PM Novel Salvage Therapy Andre Goy, MD, MS Hackensack University Medical Center, Hackensack, New Jersey, USA
3:50 PM Who Is a Candidate for Watch and Wait Therapy Anita Kumar, MD Memorial Sloan-Kettering Cancer Center, New York, New York, USA
4:05 PM Oral Abstract
   
SESSION XII: CELLULAR THERAPY
Session Chairs: Sergio Giralt and Renier Brentjens
4:15 PM Off the Shelf CAR T Cells Ewelina Morawa, MD CRISPR Therapeutics, Cambridge, Massachusetts, USA
4:30 PM NK CAR Katy Rezvani, MD, PhD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
4:45 PM Not All About CARs-Future of CTL’s Catherine Bollard, MD, MBChB National Childrens Hospital, Washington, DC, USA
5:00 PM Conduct of Adoptive T Cell Therapies Federick Locke, MD H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
5:15 PM Oral Abstract
   
5:25 PM ADJOURN    
INDUSTRY EXPERT HORS D’OEUVRES AND DRINKS SESSION V
5:30 PM Industry Expert Session: Hors d’Oeuvres and Drinks
INDUSTRY EXPERT DINNER SESSION VI
6:30 PM XOSPATA® (gilteritinib): A Targeted Therapeutic Approach for Relapsed/Refractory FLT3m+ AML Patients
This activity is supported by Astellas
SATURDAY, SEPTEMBER 14, 2019
TIME TOPIC/SESSION SPEAKER AFFILIATION/ROOM
INDEPENDENT SATELLITE SYMPOSIUM IV
6:15 AM CONSENSUS OR CONTROVERSY? Clinical Investigator Perspectives on the Current and Future Management of Patients with Chronic Lymphocytic Leukemia
This CME activity is provided by Research To Practice. This activity is supported by educational grants from AbbVie Inc; AstraZeneca Pharmaceuticals LP; and Pharmacyclics LLC, An AbbVie Company.
BREAKFAST WITH THE EXPERT IV
6:45 AM Breakfast With the Expert: Sequential vs Combination Therapy in CLL John C. Byrd, MD Ohio State University, James Comprehensive Cancer Center, Columbus, Ohio, USA
7:45 AM BREAK    
SESSION XIII: CHRONIC LYMPHOCYTIC LEUKEMIA
Session Chairs: Susan O’Brien and Emili Montserrat
8:00 AM CLL: State of the Art Update Jennifer R. Brown, MD, PhD Dana-Farber Cancer Institute, Boston, Massachusetts, USA
8:15 AM Shifting SOC for Frontline Therapy of CLL Nitin Jain, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
8:30 AM Next Generation Small Molecules Jennifer A. Woyach, MD Ohio State University, James Comprehensive Cancer Center, Columbus, Ohio, USA
8:45 AM Case Presentation: Alessandra Ferrajoli, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
9:00 AM CAR-T Cell Therapy in CLL Tanya Siddiqi, MD City of Hope National Medical Center, Duarte, California, USA
9:15 AM How Have Prognostic Factors Changed with Novel Therapies Adrian U. Wiestner, MD, PhD National Cancer Institute, Bethesda, Maryland, USA
9:30 AM Oral Abstract
   
9:40 AM Oral Abstract
   
9:50 AM BREAK    
SESSION XIV: NEXT QUESTIONS
Session Chairs: Hagop Kantarjian and TBD
10:20 AM Next Questions: Acute Lymphoblastic Leukemia Hagop Kantarjian, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
10:30 AM Next Questions: Acute Myeloid Leukemia Eunice S. Wang, MD Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA
10:40 AM Next Questions: Cellular Therapy: Point of Care CAR T Cell Boro Dropulic, PhD Lentigen Technology, Inc., Miltenyi Corporation, Gaithersburg, Maryland, USA
10:50 AM Next Questions: Chronic Lymphocytic Leukemia William Wierda, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
11:00 AM Next Questions: Chronic Myeloid Leukemia Elias Jabbour, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
11:10 AM Next Questions: Aggressive B-Cell Lymphoma Anas Younes, MD Memorial Sloan-Kettering Cancer Center, New York, New York, USA
11:20 AM Next Questions: Indolent B-Cell Lymphoma Robert Marcus, MA, FRCP, FRCPath Leaders in Oncology Care, London, United Kingdom
11:30 AM Next Questions: T-Cell Lymphoma Owen A. O’Connor, MD, PhD Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, USA
11:40 AM Next Questions: Mantle Cell Lymphoma Simon Rule, MD University of Plymouth, Derriford Hospital, Plymouth, United Kingdom
11:50 AM Next Questions: Hodgkin Lymphoma Stephen M. Ansell, MD, PhD Mayo Clinic Rochester, Minnesota, USA
12:00 PM Next Questions: Myelodysplastic Syndromes Guillermo Garcia-Manero, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
12:10 PM Next Questions: Myeloproliferative Neoplasms Srdan Verstovsek, MD, PhD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
12:20 PM POSTER AWARDS, DRAWING AND CLOSING REMARKS
12:35 PM ADJOURN